Answers are grounded in this paper and cite their sources.
This multicenter cohort study assessed the impact of COVID-19 on kidney function in kidney transplant recipients (KTRs) at 12 months after SARS-CoV-2 infection. The final analytic cohort comprised 1,145 KTRs diagnosed with COVID-19 between March-2020 and December-2021, after exclusion of patients who died or experienced graft loss within 90 days of diagnosis. Kidney function at one year was evaluated, as were variables associated with graft loss or a decline in estimated glomerular filtration rate (eGFR) ≥30% from baseline. eGFR trajectories were analyzed using a multi-step missing-data approach. At the time of COVID-19 diagnosis, the median time from transplantation was 5.9 years (IQR 2.5–10.4), and the median eGFR was 52 mL/min/1.73m² (IQR 38–68). The cumulative incidence of acute rejection at 12 months was 1.0%; 3.1% of patients died and 3.3% experienced graft loss. Mean eGFR declined by 3.77 mL/min/1.73m² (95%CI, −4.70 to −2.83) in the imputed dataset. In multivariable analysis, diabetes (OR 1.56; 95%CI 1.05–2.33;p = 0.029), hospitalization during COVID-19 (OR 1.79; 95%CI 1.19–2.69;p = 0.005), and acute rejection (OR 16.67; 95%CI 4.59–60.57;p < 0.001) were independently associated with the composite outcome of graft loss or ≥30% decline in eGFR, whereas higher baseline eGFR was protective (OR 0.89 per 10 mL/min/1.73m² increase; 95%CI 0.82–0.97;p = 0.007). In conclusion, although acute rejection and graft loss were uncommon, COVID-19 was associated with a statistically significant reduction in eGFR over 12 months that exceeded the trajectory previously reported for stable KT cohorts, raising concerns about long-term graft outcomes.
No takes yet. Share an insight, caveat, or question.
Sandes‐Freitas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: